Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Industry performance is calculated based on the previous closing price of all industry constituents
Largest Companies in This Industry
Name | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 397.48 | 465.42 | 15.18% | Buy | ||||
| 883.20 | 1,051.33 | 14.32% | Buy | ||||
| 107.97 | 132.36 | 6.26% | Buy | ||||
| 143.31 | 222.41 | 2.68% | Buy | ||||
| 28.00 | 45.50 | 2.47% | Buy | ||||
| 80.91 | 110.10 | 2.27% | Buy | ||||
| 329.83 | 324.17 | 1.86% | Hold | ||||
| 128.77 | 165.89 | 1.79% | Buy | ||||
| 51.68 | 74.29 | 1.71% | Buy | ||||
| 233.85 | 292.25 | 1.63% | Buy |
Investing in the Biotechnology Industry
Start Investing in Biotechnology Through These Companies
Top Performing Companies
Name | Last Price | 1Y Target Est. | YTD Return |
|---|---|---|---|
| 22.31 | 12.71 | ||
| 15.72 | 34.00 | ||
| 34.25 | 55.00 | ||
| 13.00 | 22.50 | ||
| 47.39 | 58.29 |
High Growth Companies
Name | Last Price | Growth Estimate | YTD Return |
|---|---|---|---|
| 14.56 | |||
| 12.45 | |||
| 5.07 | |||
| 156.88 | |||
| 21.38 |
Biotechnology Research
Discover the Latest Analyst and Technical Research for This Industry
Daily – Vickers Top Insider Picks for 04/26/2024
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Buyers & Sellers for 04/26/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: BioMarin Pharmaceutical Inc.
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
RatingPrice TargetAnalyst Report: Incyte Corp.
Founded in 1991 and based in Wilmington, Delaware, Incyte is a drug discovery and development company. The company has several small-molecule compounds in clinical trials, while its primary revenue-generating products include Jakafi, Opzelura, Iclusig, Pemazyre, and Olumiant. Jakafi treats polycythemia vera (PV), a type of blood cancer; myelofibrosis (MF), a rare bone marrow disorder; and steroid-refractory acute graft-versus-host-disease (GVHD), while Opzelura treats eczema and vitiligo, Iclusig treats leukemia, Pemazyre treats bile duct cancer, and Olumiant treats rheumatoid arthritis. The company also recently launched Tabrecta, for non-small-cell lung cancer, and has several active Phase 2 and 3 programs in oncology.
RatingPrice Target